铁过载通过抑制TP53信号通路来调解AML中的细胞因子抗性
1Department of Hematology, Affiliated Hospital of Jining Medical University, Jining 272000, China.
Acta biochimica et biophysica Sinica
|April 15, 2025
概括
急性髓性白血病 (AML) 细胞中的铁过载抑制TP53通路,降低对化疗的敏感性. 这种铁介导的耐药性涉及TFR1,影响治疗结果.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 化疗是急性髓性白血病 (AML) 的主要治疗方法,但耐药性导致治疗失败和复发.
- 铁过载在AML患者中很常见,原因是血液形成抑制和输血等因素.
- 铁过载在AML进展和化疗耐药性中的作用尚未完全理解.
研究的目的:
- 调查铁过载对AML细胞中细胞氨基酸耐药性的机制.
- 探索TP53信号通路和TFR1在铁介导化学阻力中的参与.
主要方法:
- 使用铁酸盐在AML细胞中建立了一个铁过载模型.
- 评估TP53-野生型和TP53-突变型AML细胞对cytarabine的敏感性.
- 分析了铁过载对TP53/BCL2/BAX信号通路的影响.
- 研究了TFR1在铁的吸收和化学抵抗中的作用.
主要成果:
- 与TP53-野生型细胞相比,TP53-突变AML细胞对细胞氨基酸的耐药性增加.
- 降低野生型AML细胞中的TP53表达,降低了它们对cytarabine的敏感性.
- 铁过载抑制了TP53/BCL2/BAX通路,抵消了细胞氨酸诱导的亡.
- TFR1被确定为铁吸收的关键调解者,有助于TP53野生型AML细胞中对细胞氨基酸的抵抗.
结论:
- 在AML中,TP53信号通路对于细胞氨酸诱导的亡至关重要.
- 铁过载通过抑制TP53通路促进AML化学抵抗.
- 在AML中,TFR1在铁过载诱导的抗细胞氨酸耐药性方面发挥着重要作用.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K


